The future prospects for IRLAB Therapeutics AB's mesdopetam, and the firm's partnership with Ipsen SA, are looking shakier after the investigational Parkinson's disease drug missed its primary goal in a mid-stage study.
The Swedish firm has unveiled top-line results from a Phase IIb trial of mesdopetam in levodopa-induced dyskinesia, involuntary movements that can occur after prolonged treatment with levodopa, the foundation treatment for Parkinson's
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?